TEST:

GUARDANT SHIELD

The Shield blood test uses a multimodal approach, integrating genomics, epigenomics and proteomics, to detect colorectal cancer signals in the bloodstream, including DNA that is shed by tumors, called circulating tumor DNA (ctDNA). Shield demonstrated sensitivity of 91% in colorectal cancer and 20% in advanced adenoma detection with 92% specificity (true negative rate) in normal cases in validation studies.